PMID- 33030036
OWN - NLM
STAT- MEDLINE
DCOM- 20201019
LR  - 20240329
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 26
DP  - 2020 Jan-Dec
TI  - Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, 
      Sulodexide and Its Components.
PG  - 1076029620954913
LID - 10.1177/1076029620954913 [doi]
LID - 1076029620954913
AB  - INTRODUCTION: Sulodexide represents a mixture of fast-moving heparin (FMH) and 
      dermatan sulfate (DS) and has been used for the management of venous diseases 
      such as DVT and related disorders. The purpose of this study is to compare 
      sulodexide and its components with unfractionated heparin (UFH) to determine its 
      suitability for the indications in which UFH is used. MATERIALS AND METHOD: 
      Active pharmaceutical ingredients (API) versions of sulodexide, FMH and DS were 
      obtained from Alfasigma. API versions of UFH were obtained from Medefil Inc. 
      Normal human citrated plasma was obtained from blood bank of the Loyola 
      University Medical Center. Each of the individual agents were supplemented in 
      plasma at a graded concentration of 0.0-10 microg/mL. Clotting assays (PiCT, aPTT, PT 
      and TT), anti-Xa and anti-IIa and thrombin generation studies were carried out. 
      Results were compiled as mean +/- SD of 3 individual determination. RESULT: In the 
      clot based (PiCT, aPTT and TT), anti-Xa and IIa assays, both the UFH and FMH 
      produced stronger activities in these assays followed by sulodexide. DS did not 
      show any anticoagulant activity. In the thrombin generation assay, FMH and UFH 
      produced comparable inhibition of thrombin generation as measured by various 
      parameters. Sulodexide was slightly weaker in this assay, whereas DS produced 
      relatively weaker effects. CONCLUSION: In comparison to sulodexide, both UFH and 
      FMH exhibit comparable anticoagulant activity despite differences in their 
      molecular weight. These results suggest that sulodexide can be developed as a 
      parenteral anticoagulant for indications in which UFH is used.
FAU - Siddiqui, Fakiha
AU  - Siddiqui F
AUID- ORCID: 0000-0002-2219-7049
AD  - Department of Pathology and Laboratory Medicine, Cardiovascular Research 
      Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
FAU - Hoppensteadt, Debra
AU  - Hoppensteadt D
AUID- ORCID: 0000-0001-9342-4213
AD  - Department of Pathology and Laboratory Medicine, Cardiovascular Research 
      Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
AD  - Department of Pharmacology and Neuroscience, Cardiovascular Research Institute, 
      Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
FAU - Bontekoe, Emily
AU  - Bontekoe E
AD  - Department of Pathology and Laboratory Medicine, Cardiovascular Research 
      Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
FAU - Farooqui, Ambar
AU  - Farooqui A
AD  - Department of Pathology and Laboratory Medicine, Cardiovascular Research 
      Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
FAU - Jeske, Walter
AU  - Jeske W
AD  - Department of Pathology and Laboratory Medicine, Cardiovascular Research 
      Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
AD  - Department of Thoracic and Cardiovascular Surgery, Cardiovascular Research 
      Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
FAU - Fareed, Jawed
AU  - Fareed J
AUID- ORCID: 0000-0003-3465-2499
AD  - Department of Pharmacology and Neuroscience, Cardiovascular Research Institute, 
      Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Anticoagulants)
RN  - 0 (Antithrombins)
RN  - 0 (Glycosaminoglycans)
RN  - 75HGV0062C (glucuronyl glucosamine glycan sulfate)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.21.5 (Thrombin)
SB  - IM
MH  - Anticoagulants/administration & dosage/*pharmacology
MH  - Antithrombins/administration & dosage/pharmacology
MH  - Blood Coagulation/*drug effects
MH  - Glycosaminoglycans/administration & dosage/*pharmacology
MH  - Heparin/administration & dosage/pharmacology
MH  - Humans
MH  - Italy
MH  - Sensitivity and Specificity
MH  - Thrombin/administration & dosage/*pharmacology
PMC - PMC7549168
OTO - NOTNLM
OT  - COVID-19
OT  - dermatan sulfate
OT  - fast moving heparin
OT  - sulodexide
OT  - thrombin generation inhibition
OT  - unfractionated heparin
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2020/10/09 06:00
MHDA- 2020/10/21 06:00
PMCR- 2020/10/08
CRDT- 2020/10/08 08:44
PHST- 2020/10/08 08:44 [entrez]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2020/10/08 00:00 [pmc-release]
AID - 10.1177_1076029620954913 [pii]
AID - 10.1177/1076029620954913 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620954913. doi: 
      10.1177/1076029620954913.